Sun Pharma Q3 Net Profit Jumps 16% to Rs 3,369 Cr, Driven by Broad Growth

• Sun Pharmaceutical Industries reported a 16% increase in consolidated net profit, reaching Rs 3,369 crore for Q3 FY25.
• The net profit for the October-December quarter of the previous fiscal year was Rs 2,903 crore.
• Total revenue from operations rose to Rs 15,520 crore, up from Rs 13,675 crore in the year-ago period.
• The growth was attributed to strong performance across all business segments, including India, emerging markets, and global innovative medicines.
• The board approved an interim dividend of Rs 11 per equity share for FY25-26, and new products Unloxcyt and Ilumya were launched.

Why It Matters: Sun Pharma's Q3 net profit surged 16% to Rs 3,369 crore, fueled by robust growth across all segments.